Results 271 to 280 of about 354,000 (376)

A Cytotoxic Indazole‐based Gold(III) Carboxamide Pincer Complex Targeting DNA Through Dual Binding Modes of Groove Binding and Alkylation

Chemistry – A European Journal, EarlyView.
Toward new gold(III) anticancer agents. Herein, we report on an indazole‐based gold(III) carboxamide pincer complex exhibiting significant cytotoxicity, likely mediated through dual interactions with DNA. Mechanistic investigations suggest that the complex binds to the DNA and forms specific interactions with nucleotide bases.
Rufaro Razuwika, Sheldon Sookai, Ruth Aronson, Mandeep Kaur, Orde Q. Munro   +4 more
wiley   +1 more source

The use of strong analgesics for prehospital pain management in children in the region of Southern Denmark: a register-based study. [PDF]

Scand J Trauma Resusc Emerg Med
Colding-Jørgensen JT, Brandstrup GMG, Nielsen VML, Gradman J, Thybo LAB, Hansen PM, Wittrock D, Blomberg SNF, Christensen HC, Mikkelsen S.   +9 more
europepmc   +1 more source

Exploring Tyramine's Role in the Formation of Supramolecular Adducts with Nonsteroidal Anti‐Inflammatory Drugs

Chemistry – A European Journal, EarlyView.
An a priori design approach identified tyramine as an ideal co‐former for obtaining new supramolecular adducts with nonsteroidal anti‐inflammatory drugs, speeding up the co‐crystallization process. Three novel adducts and a new polymorphic form were synthesized and thoroughly characterized by solid‐state NMR and single‐crystal XRD.
Chiara Rosso, Rebecca Birolo, Angelo Gallo, William T. Franks, Emanuele Priola, Michele R. Chierotti, Roberto Gobetto   +6 more
wiley   +1 more source

Pain assessment and management of adult patients in the Swedish EMS: a nationwide registry study. [PDF]

Scand J Trauma Resusc Emerg Med
Larsson G, Wennberg P, Wibring K.
europepmc   +1 more source

Drug Interaction in the Field of Analgesic Drugs

, 1965
Louis Lasagna
openalex   +1 more source

Spontaneous renal pelvis rupture with peri-nephric abscess and stone extrusion: A case report. [PDF]

Urol Case Rep
Karna S.
europepmc   +1 more source

Isoniazid‐Dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation

ChemMedChem, EarlyView.
Antitubercular evaluation of a novel library of isoniazid‐dihydropyrimidinone molecular hybrids (8a–8n) discloses a potent compound with MIC = 0.39μg mL−1 against M. tuberculosis mc26230. Cytotoxicity, stability, and in silico studies, including molecular docking and ADME/T (absorption, distribution, metabolism, excretion, and toxicity) analysis ...
Gobind Kumar, Pule Seboletswe, Sahil Mishra, Neha Manhas, Safiyah Ghumran, Nagaraju Kerru, Françoise Roquet‐Banères, Maëlle Foubert, Laurent Kremer, Gaurav Bhargava, Parvesh Singh   +10 more
wiley   +1 more source

Improving Antiemetic and Analgesic Prescribing Practices for Patients With Advanced Liver Disease: A Clinical Audit. [PDF]

Cureus
Baird D, Calvert S, Finlay F.
europepmc   +1 more source

Further SAR of GIRK1/2 activators: Synthesis and Biological Characterization of In Vitro Tool Compounds

ChemMedChem, Accepted Article.
The work presented herein outlines the ongoing structure‐activity relationship (SAR) studies centered around a potent, efficacious, and selective activators of the GIRK1/2 channel. Optimization studies centered around the pyrazole privileged scaffold, the N‐1‐position of the pyrazole and the right‐hand ether.
Sumaiya Nahid, Fahad Imtiaz Rahman, Yu Du, Brittany Spitznagel, Sandeep K Singh, Yashpal Chhonker, Daryl J Murry, David Weaver, Corey R Hopkins   +8 more
wiley   +1 more source

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source